**3. Therapeutic proposals: antithrombotic treatment**

The recognition of thrombosis as a key contributor to clinical deterioration and death has led to a worldwide interest in the study of optimal antithrombotic treatment doses for patients. Clinical trials have shown that the efficacy and safety of these treatments vary according to the time course of the disease [21]. For this reason, treatment should be started early in the Emergency Department in all hospitalised patients and assessed according to thrombotic and haemorrhagic risk factors [22]. Haematological and coagulation parameters (e.g. D-dimer, prothrombin time, platelet count, fibrinogen) are commonly measured. Evidence shows that elevated D-dimer values correlate positively with disease severity and prognosis [23]. However, at present, there is insufficient evidence to recommend for or against the use of these data to guide management decisions [7, 24]. Dosing recommendations are dynamic and have changed throughout the pandemic. The results of recent scientific publications have generated controversy about the best strategy for antithrombotic prophylaxis and treatment, which is reflected in the variability of consensus recommendations published by different scientific organisations and societies [25]. In terms of treatment, we differentiate between non-hospitalised and hospitalised patients.
